Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Friday, March 15th.

Cytosorbents Trading Up 7.4 %

Shares of NASDAQ CTSO traded up $0.06 during mid-day trading on Thursday, reaching $0.88. 109,450 shares of the company’s stock were exchanged, compared to its average volume of 93,292. The company’s 50-day moving average is $0.91 and its 200-day moving average is $1.14. Cytosorbents has a 52-week low of $0.78 and a 52-week high of $4.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The company had revenue of $8.67 million for the quarter, compared to analyst estimates of $9.29 million. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. As a group, analysts forecast that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently bought and sold shares of the stock. Key Client Fiduciary Advisors LLC raised its holdings in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 22,557 shares in the last quarter. Avenir Corp increased its position in shares of Cytosorbents by 12.3% in the 4th quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after purchasing an additional 334,005 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares during the last quarter. Skylands Capital LLC raised its holdings in shares of Cytosorbents by 10.5% in the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after purchasing an additional 309,543 shares in the last quarter. Finally, Sargent Investment Group LLC lifted its position in shares of Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.